SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Friedman SL, Bansal MB. Reversal of hepatic fibrosis—fact or fantasy? Hepatology 2006; 43 Suppl 1: S828.
  • 2
    Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 2137.
  • 3
    Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 55767.
  • 4
    Idriss HT, Naismith JH. TNFα and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 2000; 50: 18495.
  • 5
    Beyaert R, Fiers W. Molecular mechanisms of tumor necrosis factor-induced cytotoxicity: what we do understand and what we do not. FEBS Lett 1994; 340: 916.
  • 6
    Watts AD, Hunt NH, Hambly BD, Chaudhri G. Separation of tumor necrosis factor α isoforms by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 1997; 18: 108691.
  • 7
    Loetscher H, Steinmetz M, Lesslauer W. Tumor necrosis factor: receptors and inhibitors. Cancer Cells 1991; 3: 2216.
  • 8
    Beutler B, Bazzoni F. TNF, apoptosis and autoimmunity: a common thread? Blood Cells Mol Dis 1998; 24: 21630.
  • 9
    Kalthoff H, Roeder C, Brockhaus M, Thiele HG, Schmiegel W. Tumor necrosis factor (TNF) up-regulates the expression of p75 but not p55 TNF receptors, and both receptors mediate, independently of each other, up-regulation of transforming growth factor α and epidermal growth factor receptor mRNA. J Biol Chem 1993; 268: 27626.
  • 10
    Rothe J, Bluethmann H, Gentz R, Lesslauer W, Steinmetz M. Genomic organization and promoter function of the murine tumor necrosis factor receptor β gene. Mol Immunol 1993; 30: 16575.
  • 11
    Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 1995; 5: 3929.
  • 12
    Barbara JA, Smith WB, Gamble JR, Van Ostade X, Vandenabeele P, Tavernier J, et al. Dissociation of TNF-α cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-α mutants. EMBO J 1994; 13: 84350.
  • 13
    Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 2004; 63 Suppl 2: ii212.
  • 14
    Keyser FD, Mielants H, Veys EM. Current use of biologicals for the treatment of spondyloarthropathies. Expert Opin Pharmacother 2001; 2: 8593.
  • 15
    Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350: 216779.
  • 16
    Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007; 34: 16367.
  • 17
    Bosello S, De Santis M, Tolusso B, Zoli A, Ferraccioli G. Tumor necrosis factor-α inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann Intern Med 2005; 143: 91820.
  • 18
    Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 12815.
  • 19
    Antoniou KM, Mamoulaki M, Malagari K, Kritikos HD, Bouros D, Siafakas NM, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007; 25: 238.
  • 20
    Denton CP, Engelhart M, Tvede N, Khan K, Carreira PE, Gonzalez FD, et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S524.
  • 21
    Ellman MH, MacDonald PA, Hayes FA. Etanercept as treatment for diffuse scleroderma: a pilot study [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S392.
  • 22
    Ellman MH, MacDonald PA, Katz RS. Open label use of etanercept in eight scleroderma patients [abstract]. Ann Rheum Dis 2003; 62 Supp I: 229.
  • 23
    Allanore Y, Devos-Francois G, Caramella C, Boumier P, Jounieaux V, Kahan A. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 2006; 65: 8345.
  • 24
    Ostor AJ, Crisp AJ, Somerville MF, Scott DG. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 2004; 329: 1266.
  • 25
    Mauviel A, Daireaux M, Redini F, Galera P, Loyau G, Pujol JP. Tumor necrosis factor inhibits collagen and fibronectin synthesis in human dermal fibroblasts. FEBS Lett 1988; 236: 4752.
  • 26
    Mauviel A, Heino J, Kahari VM, Hartmann DJ, Loyau G, Pujol JP, et al. Comparative effects of interleukin-1 and tumor necrosis factor-α on collagen production and corresponding procollagen mRNA levels in human dermal fibroblasts. J Invest Dermatol 1991; 96: 2439.
  • 27
    Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A, et al. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor α. Arthritis Rheum 2003; 48: 2593604.
  • 28
    Kouba DJ, Chung KY, Nishiyama T, Vindevoghel L, Kon A, Klement JF, et al. Nuclear factor-κB mediates TNF-α inhibitory effect on α2(I) collagen (COL1A2) gene transcription in human dermal fibroblasts. J Immunol 1999; 162: 422634.
  • 29
    Verrecchia F, Wagner EF, Mauviel A. Distinct involvement of the Jun-N-terminal kinase and NF-κB pathways in the repression of the human COL1A2 gene by TNF-α. EMBO Rep 2002; 3: 106974.
  • 30
    Verrecchia F, Pessah M, Atfi A, Mauviel A. Tumor necrosis factor-α inhibits transforming growth factor-β/Smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem 2000; 275: 3022631.
  • 31
    Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162: 21638.
  • 32
    Meikle MC, Atkinson SJ, Ward RV, Murphy G, Reynolds JJ. Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interleukin 1: evidence that breakdown is mediated by metalloproteinases. J Periodontal Res 1989; 24: 20713.
  • 33
    Ito A, Sato T, Iga T, Mori Y. Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts. FEBS Lett 1990; 269: 935.
  • 34
    Armendariz-Borunda J, Katayama K, Seyer JM. Transcriptional mechanisms of type I collagen gene expression are differentially regulated by interleukin-1β, tumor necrosis factor α, and transforming growth factor β in Ito cells. J Biol Chem 1992; 267: 1431621.
  • 35
    Theiss AL, Simmons JG, Jobin C, Lund PK. Tumor necrosis factor (TNF) α increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem 2005; 280: 36099109.
  • 36
    Sullivan DE, Ferris M, Pociask D, Brody AR. Tumor necrosis factor-α induces transforming growth factor-β1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol 2005; 32: 3429.
  • 37
    McCulloch CA, Knowles GC. Deficiencies in collagen phagocytosis by human fibroblasts in vitro: a mechanism for fibrosis? J Cell Physiol 1993; 155: 46171.
  • 38
    Chou DH, Lee W, McCulloch CA. TNF-α inactivation of collagen receptors: implications for fibroblast function and fibrosis. J Immunol 1996; 156: 435462.
  • 39
    Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, Graham FL, et al. Transfer of tumor necrosis factor-α to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-β1 and myofibroblasts. Am J Pathol 1998; 153: 82532.
  • 40
    Feghali-Bostwick CA, Tsai CG, Valentine VG, Kantrow S, Stoner MW, Pilewski JM, et al. Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol 2007; 179: 25929.
  • 41
    Miyazaki Y, Araki K, Vesin C, Garcia I, Kapanci Y, Whitsett JA, et al. Expression of a tumor necrosis factor-α transgene in murine lung causes lymphocytic and fibrosing alveolitis: a mouse model of progressive pulmonary fibrosis. J Clin Invest 1995; 96: 2509.
  • 42
    Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-α. Circ Res 1997; 81: 62735.
  • 43
    Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor α can be modulated by anti-tumor necrosis factor α therapy. Proc Natl Acad Sci U S A 2000; 97: 1274651.
  • 44
    Piguet PF, Grau GE, Vassalli P. Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am J Pathol 1990; 136: 10310.
  • 45
    Fujita M, Shannon JM, Morikawa O, Gauldie J, Hara N, Mason RJ. Overexpression of tumor necrosis factor-α diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-β. Am J Respir Cell Mol Biol 2003; 29: 66976.
  • 46
    Buck M, Houglum K, Chojkier M. Tumor necrosis factor-α inhibits collagen α1(I) gene expression and wound healing in a murine model of cachexia. Am J Pathol 1996; 149: 195204.
  • 47
    Houglum K, Buck M, Kim DJ, Chojkier M. TNF-α inhibits liver collagen-α1(I) gene expression through a tissue-specific regulatory region. Am J Physiol 1998; 274: G8407.
  • 48
    Piguet PF, Collart MA, Grau GE, Sappino AP, Vassalli P. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature 1990; 344: 2457.
  • 49
    Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994; 7: 5158.
  • 50
    Farivar AS, Mackinnon-Patterson B, McCourtie AS, Namkung J, Ward PA, Mulligan MS. Obliterative airway disease in rat tracheal allografts requires tumor necrosis factor α. Exp Mol Pathol 2005; 78: 1907.
  • 51
    Khan SB, Cook HT, Bhangal G, Smith J, Tam FW, Pusey CD. Antibody blockade of TNF-α reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 2005; 67: 181220.
  • 52
    Liu JY, Brass DM, Hoyle GW, Brody AR. TNF-α receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am J Pathol 1998; 153: 183947.
  • 53
    Ortiz LA, Lasky J, Hamilton RF Jr, Holian A, Hoyle GW, Banks W, et al. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res 1998; 24: 72143.
  • 54
    Ortiz LA, Lasky J, Lungarella G, Cavarra E, Martorana P, Banks WA, et al. Upregulation of the p75 but not the p55 TNF-α receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am J Respir Cell Mol Biol 1999; 20: 82533.
  • 55
    Guo G, Morrissey J, McCracken R, Tolley T, Klahr S. Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol 1999; 277: F76672.
  • 56
    Guo G, Morrissey J, McCracken R, Tolley T, Liapis H, Klahr S. Contributions of angiotensin II and tumor necrosis factor-α to the development of renal fibrosis. Am J Physiol Renal Physiol 2001; 280: F77785.
  • 57
    Kitamura K, Nakamoto Y, Akiyama M, Fujii C, Kondo T, Kobayashi K, et al. Pathogenic roles of tumor necrosis factor receptor p55-mediated signals in dimethylnitrosamine-induced murine liver fibrosis. Lab Invest 2002; 82: 57183.
  • 58
    Sudo K, Yamada Y, Moriwaki H, Saito K, Seishima M. Lack of tumor necrosis factor receptor type 1 inhibits liver fibrosis induced by carbon tetrachloride in mice. Cytokine 2005; 29: 23644.
  • 59
    Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, et al. Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006; 55: 41524.